Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP
Corbus Pharmaceuticals — Investor Presentation (June 2024)
73 slides from Corbus Pharmaceuticals's investor presentation, Jun 3, 2024
Slide 1: Connecting Innovation to Purpose
Connecting Innovation to Purpose NASDAQ: CRBP Corporate Presentation June 1, 2024 Exhibit 99.2
Slide 2: Forward-Looking Statements
This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, prod
Slide 3: Investment Summary
Investment Summary $120M Cash, cash equivalents and investments as of March 31, 2024 10.5M Common Shares Outstanding (11. 6M Fully-Diluted Shares) Nectin-4 targeting ADC for treatment of solid tumors Oral CB1R inverse agonist to treat obesity TGFβ blocker Anti-⍺vβ8 integrin mAb for treatment of soli
Slide 4: A Diversified Pipeline with Differentiated Clinical Risk Profiles
Therapy Disease Indication Sponsor Pre-Clinical Phase 1 Phase 2 Phase 3 Milestones Next-Generation Nectin-4 targeting ADC CRB-701 Next-generation Nectin-4 targeting ADC Nectin-4 positive solid tumors CSPC (China) Cohort 6 Expanding Corbus (US + Europe) First Patient Dosed Anti-Integrin mAb CRB-601 A
Slide 5: CRB-701 Next Generation Nectin-4 Targeting ADC
CRB-701 Next Generation Nectin-4 Targeting ADC
Slide 6: Padcev Projected to Reach Up to ~$5B in Global Sales
Padcev® Projected to Reach Up to ~$5B in Global Sales by 2028 Sources: 1. SGEN press release, October 2023, 2. Evaluate Pharma PADCEV® Global Projected Revenues in UC/Bladder2 $5B Latest Padcev® Q3 revenues 1 22nd October 2023 2 ® Groundbreaking EV-302 Trial Significantly Extends Overall Survival an
Slide 7: Does Tolerability for Padcev Impact Clinical Adoption?
Does Tolerability for Padcev® Impact Clinical Adoption? Source(s): PADCEV® Prescribing Information as of Apr 2023. Duration of Response~5 months 47% Rate of Serious Adverse Events (SAEs) 61% Dose Interruptions 34% Dose Reductions 17% Dose Discontinuations Revised: 4/2023 PADCEV® Prescribing Informat
Slide 8: Padcev is Associated with Skin Toxicities and Peripheral Neuropathy
Padcev® is Associated with Skin Toxicities and Peripheral Neuropathy Source(s): 1. PADCEV® Prescribing Information Dec 2023. 2.. Rosenberg et al., 2020 Adverse Events (% of Patients) ® A Black Box Warning1 Greater than 25% of PADCEV® discontinuations are linked to peripheral neuropathy 2 PADCEV® + K
Slide 9: Is the 2nd Generation Seagen Linker the Cause?
ADC drug TAA Average DAR Skin Rash Peripheral Neuropathy Padcev® Enfortumab vedotin Nectin-4 3.8 Adcetris® Brentuximab vedotin CD30 4 Tivdak® Tisotumab vedotin TF 4 Polivy® Polatuzumab vedotin CD79B 3.5 Aidixi® Disitamab vedotin HER2 4 Is the 2nd Generation Seagen® Linker the Cause? Padcev® Val-Cit
Slide 10: Padcev Requires Frequent Dosing and Real-world Usage Differs from Label
6 months of therapy = ~ 54 hours of total clinic time / patient Real-world use, dose intensity, and adherence to Padcev® Padcev® Requires Frequent Dosing and Real-world Usage Differs from Label Source(s): 1. PADCEV® Prescribing Information as of Dec 2019, 2. Redacted from Tsingas et al., ASCO 2023 M
Slide 11: Designing a Nectin-4 ADC Intended to Address Padcev Unmet Needs
Nectin-4 targeting ADC for treatment of solid tumors Extend ADC half-life Reduce dosing frequency Lower DAR + longer half-life Dose higher than Padcev® Compliance Efficacy Toxicity Designing a Nectin-4 ADC Intended to Address Padcev® Unmet Needs
Slide 12: CRB-701: Next Generation Site-specific Nectin-4 Targeting ADC
CRB-701: Next Generation Site-specific Nectin-4 Targeting ADC MMAE = Monomethyl auristatin E ADCC = antibody-dependent cellular cytotoxicity. CDC = complement dependent cytotoxicity DAR = Drug Antibody Ratio Source(s): Modified image from Corbus data on file; Corbus data on file
Slide 13: CRB-701: Dosing Offers Advantages Over More Frequent Dosing
CRB-701: One Dose Every 21 Days Offers Advantages Over More Frequent Dosing Source(s): Corbus data on file; PADCEV® Prescribing Information as of Dec 2019 Padcev® CRB-701 Clinical Cycle Comparison Patient / Physician Convenience Combination Flexibility
Slide 14: ASCO 2024 Update: Dose Escalation Study (China)
ASCO 2024 Update: Phase 1 Dose Escalation Study (China) KEY ELIGIBILITY Age ≥ 18 years Advanced urothelial carcinoma or Nectin-4 positive Advanced solid tumors ECOG 0-1 Adequate organ function No uncontrolled diabetes No active CNS metastasis ESCALATION DESIGN Bayesian Optimal Interval (BOIN) design
Slide 15: ASCO 2024 Update: Demographics & Key Characteristics
ASCO 2024 Update: Demographics & Key Characteristics Characteristic Value Median age (range) 55 (35,76) Sex (M/F) 29.7%, 70.3% ECOG PS 0,1, missing 8.1%, 89.2%, 2.7% Weight in Kg mean (range) 59.01 (36.0, 84.9) Prior therapies median (range) 4.0 (0,10) Creatinine clearance <60μ mol/L 29.7% Visceral
Slide 16: ASCO 2024 Update: Safety and Dose Modifications
ASCO 2024 Update: Safety and Dose Modifications Dose Modifications n Discontinuations 0 Reductions 0 Interruptions 1 CRB-701 continues to be well tolerated with mainly grade 1 or 2 AEs Still no DLTs or Grade 4 or 5 AEs observed to date including in the 4.5 mg/Kg cohort No additional grade 3 treatmen
Slide 17: ASCO 2024 Update: TEAEs of Special Interest
ASCO 2024 Update: TEAEs of Special Interest (<20% incidence) AE of special interest Grade Dose (n out of 37) Notes Skin rash 3 2.7 mg/Kg (n=1) Resolved after 8 days (no dose change) Skin rash 2 3.6mg/Kg (n=1) Resolved after 5 weeks (no dose change) Skin rash 1 3.6 mg/Kg (n=1) Resolved after 19 days
Slide 18: Favorable Emerging Safety Profile vs. Nectin-4 ADC Competitors
Favorable Emerging Safety Profile vs. Nectin-4 ADC Competitors 1 Rosenberg, et al., JCO, 2020 Apr 1; 38(10): 1041–1049, 2. NDA/BLA Multidisciplinary Review and Evaluation BLA 761137 PADCEV™ (enfortumab vedotin-ievx), 3. BicycleTx R&D day Dec. 2023, 4. Mabwell Announces 9MW2821 Clinical Data and Late
Slide 19: ASCO 2024 Update: Pharmacokinetics
ASCO 2024 Update: Pharmacokinetics Continuing to indicate differentiation from PADCEV Delivering higher amounts of ADC at the higher doses explored Consistently less free MMAE levels across all doses tested to-date 21 Day PK Comparison %ADC %Free MMAE Cmax AUC0-21d Cmax AUC0-21d Enfortumab vedotin (
Slide 20: ASCO 2024 Update: Dose Escalation Disease Responses
ASCO 2024 Update: Phase 1 Dose Escalation Disease Responses Two of seven PRs are unconfirmed 2 previous unconfirmed PRs at ASCO GU-2024 now confirmed
Slide 21: ASCO 2024 Update: Disease Response-mUC & Cervical
ASCO 2024 Update: Disease Response-mUC & Cervical ≥ 1.2 mg/kg ORR: 43% (3 of 7 PRs) DCR: 86% ORR: 44% (4 of 9 PRs) DCR: 78% % Change by RECIST criteria
Slide 22: ASCO 2024 Update: Swimmer Plots
ASCO 2024 Update: Swimmer Plots
Slide 23: ASCO 2024 Update: Summary Data
ASCO 2024 Update: Phase 1 Summary Data Objective Response Rate in mUC at doses ≥ 1.2 mg/KG 44%: 4 out of 9 patients with PRs (1 unconfirmed, DCR-78%) Objective Response Rate in Cervical at doses≥ 1.2mg/KG 43%: 3 out of 7 patients with PRs(1 unconfirmed, DCR-86%) Dose for first observed SD 0.2 mg/Kg
Slide 24: CRB-701: A Differentiated Clinical Development Approach to Competitors
CRB-701: A Differentiated Clinical Development Approach to Competitors Proprietary insights are driving indication selection for CRB-701 New reality of Padcev® + Keytruda® 1L therapy Under-served niche mUC populations remain and are attractive targets Emerging clinical data from current dose escalat
Slide 25: CRB-701-01 Study Design
CRB-701-01 Study Design (Corbus) Dose escalation (Dosing underway) Project Optimus (dose optimization) Dose expansion at RP2D Randomized to 2 doses of CRB-701 monotherapy Randomized to 2 doses of CRB-701 +CPI 1.8 mg/Kg 2.7 mg/Kg 3.6 mg/Kg 4.5 mg/Kg Bladder cancer niche population(s) Non-UC tumors: A
Slide 26: Validation of Nectin-4 as a Tumor Associated Antigen beyond mUC
Validation of Nectin-4 as a Tumor Associated Antigen beyond mUC References: 1. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.6017 2. Efficacy and safety of 9MW2821, an antibody-drug conjugate targeting Nectin-4, monotherapy in patients with recurrent or metastatic cervical cancer: A mult
Slide 27: CRB-701 Expected Milestones
ASCO-2024 Expected Q4-2024 Expected Q1-2025 Expected Milestones Q1-2024 First patient dosed in U.S. dose escalation study Clinical data update on China dose escalation study Complete U.S. dose escalation study Present U.S. dose escalation data
Slide 28: CRB-701: Summary
CRB-701: Summary Emerging clinical safety appears differentiated to PADCEV Clinical activity seen in mUC and cervical cancer patients 3rd generation ADC with improved linker stability, reduces MMAE in circulation
Slide 29: CRB-913 Oral Cannabinoid Type-1 Inverse Agonist
CRB-913 Oral cannabinoid Type-1 inverse agonist for superior incretin therapy in obesity
Slide 30: The obesity landscape is evolving to address these issues
The obesity landscape is evolving to address these issues Degree of weight loss Quality of weight loss Muscle loss Accessibility Injectables Oral small molecules Tolerability Single MOA Multiple orthogonal MOAs
Slide 31: The Return of a Clinically-Validated Obesity Drug Class
The Return of a Clinically-Validated Obesity Drug Class CB1 Inverse Agonism
Slide 32: CB1 is a Well Understood Receptor in Metabolism
Source(s): Targeting the endocannabinoid system in diabesity: Fact or fiction?, Drug Discovery Today, Deeba et al. Mar 2021. CB1 is a Well Understood Receptor in Metabolism >9K papers in PubMed on CB1 and metabolism
Slide 33: The CB1 MOA is Clinically Validated in Obesity
The CB1 MOA is Clinically Validated in Obesity: Data From 1st Gen Drugs Source(s): 1. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia, Després et al, NEJM, Nov 2005. RIO-Lipids Phase 3 study Placebo (n=342); 5 mg rimonabant (n=345); 20 mg rimonabant (n=346) R
Slide 34: Rimonabant Weight Loss Not Associated With Reduction of Lean Mass
Body composition was measured with body DEXA in a subset of patients in RIO Lipids. Decreases in the rimonabant 20 mg group relative to placebo were observed in the total body mass (p<0.001), the total body fat mass (p=0.001) and the fat mass/total body mass ratio (p=0.007). There was no statistical
Slide 35: Muscle-CB1 KO Leads to Increase In Muscle Mass in Obese Mice
Muscle-cb1 KO Leads to Increase In Muscle Mass in Obese Mice (Gonzalez-Mariscal et al, 2019) Key finding: Muscle-CB1 KO mice… Increase in muscle mass and strength Increase in biomarkers of muscle growth Increase in mitochondrial metabolism Increase in energy expenditure Increase in calorie consumpti
Slide 36: Next Generation CB1 Inverse Agonists are Peripherally Restricted
INV-202 CRB-913 Next Generation CB1 Inverse Agonists are Peripherally Restricted Rimonabant Otenabant Ibipinabant Taranabant Source(s): Cinar et al 2020 First generation (2000-2007) Next generation (2020 onwards) Designed to target the brain with high BBB penetration FDA rejection due to safety co
Slide 37: Novo Acquisition of Inversago Marks Return of CB1 in Obesity
Single-dose INV-202 (25mg QD) N = 37 Adults with metabolic syndrome Weight loss in 28 days: -3.50 kg (INV-202) vs +0.55Kg (placebo) INV-202 (Inversago) a.k.a Monlunabant (Novo) a.k.a MRI-1891(NIH) Aug. 10, 2023 Novo Nordisk Acquisition of Inversago Marks Return of CB1 as an MOA in Obesity Source(s):
Slide 38: Monlunabant Data Predicted for H2 2024
Source: TD Cowen Research Report, May 8, 2024 by Michael Nedelcovych “Novo has modeled the weight loss achieved in Phase I and expects to see 16-19% weight loss with single agent Monlunabant at a mature time point (Phase Il obesity results anticipated in H2).” Monulabant (INV-202) Data Predicted for
Slide 39: How can a CB1 Inverse Agonist Achieve 16-19% Weight Loss?
How can a CB1 Inverse Agonist Achieve 16-19% Weight Loss? Source(s): Inversago corporate presentation Monlunabant phase 2 study: ClinicalTrials.gov ID: NCT05891834 Standard obesity endpoints + DEXA scan Standard inclusion and exclusion criteria Monlunabant daily dosing for 16 weeks:50 mg tablet=2.5X
Slide 40: CRB-913: Oral CB1 Inverse Agonist for Combination Therapy with Incretins
Nov. 2023 CRB-913: Oral CB1 Inverse Agonist for Combination Therapy with Incretins
Slide 41: CRB-913: Designed to be a Best-in-class Next Generation CB1 Inverse Agonist
Design Goals CRB-913: Designed to be a Best-in-class Next Generation CB1 Inverse Agonist Best-in-class peripheral restriction Protect lean mass (muscle) Retain 1st gen efficacy Enhance efficacy of incretin analogs
Slide 42: Oral CRB-913 is the Outcome of a Multi-year Medicinal Chemistry Campaign
Ibipinabant (2004-2008) JD-5037 (2012-2018) / CRB-4001 (2018-2021) Completed Phase IIb (Solvay/BMS) Small, lipid soluble molecule High BBB penetration Oral Same backbone as Inversago compounds (MRI/INV family) CRB-4001 (JD5037) licensed from Jenrin in 2018 Extensive pre-IND studies carried out PK di
Slide 43: CRB-913: Marked Lower Brain and Higher Peripheral Exposure Vs. Rimonabant
Source(s): Morningstar et al 2023 CRB-913: Marked ↓ Brain and ↑ Peripheral Exposure Vs. Rimonabant in Both Lean and Obese Mice 10 mg/Kg Co-administration with incretin analog does not affect brain penetration for CRB-913
Slide 44: CRB-913: Higher Degree of Peripheral Restriction than Monlunabant or Rimonabant
Source(s): *Morningstar et al 2023 and **Liu et al 2021 Brain concentration (ng/g) single acute dose CRB-913 (lean mice) Monlunabant (lean mice) Rimonabant (lean mice) 10 mg/Kg 26* 319** 561* 1:12 1:21 CRB-913: Higher Degree of Peripheral Restriction than Monlunabant or Rimonabant
Slide 45: CRB-913: Similar Weight Loss vs. Rimonabant at Same Daily Doses in DIO Mice
Source(s): Morningstar et al 2023 CRB-913: Similar Weight Loss vs. Rimonabant at Same Daily Doses in DIO Mice
Slide 46: CRB-913: Similar Weight Loss Despite Markedly Lower Brain Concentrations
21-fold DIO mouse model (day 28) DIO mouse model with C57BL6/N mice (n=10) fed a continuous high fat diet for 22 weeks prior and during 28 days of treatment Brain collected 1 h post final dose (Cmax) Source(s): Company data on file. CRB-913: Similar Weight Loss Despite Markedly Lower Brain Concentra
Slide 47: CRB-913 Demonstrates Significant Reduction in Body Fat but Not Lean Mass
weight (g) Body Fat Lean Mass CRB-913 Demonstrates Significant Reduction in Body Fat Content but Not Lean Mass DIO mouse model with C57BL6/J mice (n=10) fed a continuous high fat diet for 22 weeks prior Body fat by MRI determined on Day 20 Source(s): Morningstar et al 2023
Slide 48: CRB-913: Enhanced Combo Effect with Semaglutide Or Tirzepatide
CRB-913: Enhanced Combo Effect with Semaglutide Or Tirzepatide Source(s): Company data on file. DIO mouse model with C57BL6/J mice (n=10) fed a continuous high fat diet for 22 weeks prior and during 18 days of treatment (Similar effect also seen when CRB-913 was combined with liraglutide) Body weigh
Slide 49: CRB-913 Reduces Food Consumption Alone or in Combination
Food Consumption CRB-913, semaglutide and tirzepatide each results in food intake reductions Significant further reductions in food consumption when CRB-913 is combined with semaglutide or tirzepatide (p=0.001) All cohorts P < 0.001 compared with vehicle DIO mouse model with C57BL6/J mice (n=10) fed
Slide 50: CRB-913 Reverses Leptinemia Alone and in Combination
CRB-913 Reverses Leptinemia Alone and in Combination with Semaglutide or Tirzepatide Source(s): 1 Leptin and the maintenance of elevated body weight, Pan and Myers, Nature Reviews, Jan 2018. Company data on file. The Role of Leptin The hormone leptin regulates food intake Normally, leptin signals sa
Slide 51: CRB-913 Reduces Liver Fat Alone and in Combination
vehicle CRB-913 (2.5 mg/kg) semaglutide (10 nmol/kg) CRB-913 (2.5 mg/kg) + semaglutide (10 nmol/kg) tirzepatide (5 nmol/kg) CRB-913 (2.5 mg/kg) + tirzepatide (5 nmol/kg) Liver fat CRB-913 Reduces Liver Fat Alone and in Combination with Semaglutide or Tirzepatide *liver oil red stain Source(s): Compa
Slide 52: CRB-913: Clinical Development Pathway
CRB-913: Clinical Development Pathway Q4 2024 H1 2025 H2 ‘25 – H1 ‘26 H2 ‘26 – H1 ‘27 SAD MAD IND Monotherapy 28 days (3 doses) Co-admin with incretin analog
Slide 53: CRB-913: Potential Clinical Usage
CRB-913: Potential Clinical Usage Incretin analog therapy for insensitive/intolerant/high-risk patients Combination with oral incretin agonists potentially enhances efficacy OR improve tolerability “Induction/maintenance” model: goal to potentially maintain weight loss post incretin analog therapy
Slide 54: Expected Milestones
Expected Milestones Produce drug for toxicology and clinical studies Q2-2024 Complete toxicology and IND enabling studies Q4-2024 FPI SAD/MAD Q1-2025
Slide 55: Leadership, Upcoming Catalysts, Financials
Leadership Upcoming Catalysts Financials
Slide 56: Management Team
Management Team Sean Moran, CPA, MBA Chief Financial Officer Corbus co-founder and Chief Financial Officer since 2014. Prior senior financial management experience in emerging biotech and medical device companies. Christina Bertsch Head of Human Resources Accomplished senior human resource executive
Slide 57: Board of Directors
Board of Directors Amb. Alan Holmer Ret. Chairman of the Board More than two decades of public service in Washington, D.C. including Special Envoy to China; Former CEO of PhRMA. Avery W. (Chip) Catlin Director More than 25 years of senior financial leadership experience in life science companies; For
Slide 58: Expected Corporate Milestones
Expected Corporate Milestones First patient dosed: Summer 2024 First patient dosed: early 2025 Complete U.S. dose escalation study: Q4 2024 Present U.S. dose escalation data: Q1-2025 CRB - 701 CRB-913 CRB-601
Slide 59: Investment Summary
Investment Summary $120M Cash, cash equivalents and investments as of March 31, 2024 and 10.5M Common Shares Outstanding (11.6M Fully-Diluted Shares) Nectin-4 targeting ADC for treatment of solid tumors Oral CB1R inverse agonist to treat obesity TGFβ blocker Anti-⍺vβ8 integrin mAb for treatment of s
Slide 60: Connecting Innovation to Purpose
Connecting Innovation to Purpose NASDAQ: CRBP Corporate Presentation
Slide 61: Corbus Pharmaceuticals
CORBUS %” PHARMACEUTICALS
Slide 62: CRB-601 Potential best-in-class avb8 mAb
CRB-601 Potential “best-in-class” ⍺vβ8 mAb
Slide 63: CRB-601 has the Potential to Enhance Checkpoint Inhibition
CRB-601 has the Potential to Enhance Checkpoint Inhibition Focus on adopting a precision-targeted approach Novel mechanism to target TGFb in the tumor microenvironment Large opportunity potential if POC is validated
Slide 64: TGFβ predicts poor clinical outcomes in a subset of cancer patients
TGFβ predicts poor clinical outcomes in a subset of cancer patients 0 25 20 15 10 5 0.0 0.2 0.4 0.6 0.8 1.0 N = 8,461 cancers, multiple cell types Time (years) Overall survival, % Immunogenomic subtypes in cancer Source(s): Thorsson, et al. The Immune Landscape of Cancer, Immunity. 2018; 48:817 C1 C
Slide 65: Targeting the Integrin avb8 Represents a Novel Approach to Regulating TGFβ
Targeting the Integrin ⍺Vβ8 Represents a Novel Approach to Regulating TGFβ Source(s): Huang et al., 2021. Recent progress in TGFβ inhibitors for cancer therapy.
Slide 66: CRB-601 is Targeting Latent-TGFβ by Blocking the Integrin avb8
CRB-601 is Targeting Latent -TGFβ by Blocking the Integrin avb8 The integrin avb8 is expressed in the tumor microenvironment (TME) Latent-TGFb is also expressed in the TME CRB-601 is a blocking antibody preventing the interaction of these two proteins
Slide 67: mAbs targeting TGFβ Activation are Advancing clinically
mAbs targeting TGFβ Activation are Advancing clinically Source(s): Company websites. Clinicaltrials.gov. Internal analysis. CRB-601 PF-06940434 SRK-181 ABBV-151 RG6440 MOA ⍺vβ8 ⍺vβ8 L-TGFβ GARP (TGFβ1) L-TGFβ Clinical Stage IND Cleared Jan 24 Phase 1/2 Phase 1 Phase 2 Phase 1 Indications Solid Tumor
Slide 68: CRB-601 Enhances Anti-PD-1 Therapy in Murine Tumor Models
CRB-601 Enhances Anti-PD-1 Therapy in Checkpoint Inhibition Sensitive and Resistant Murine Tumor Models CRB-601: 10 mg/kg BIW Anti-PD-1: 10 mg/kg BIW 10 animals / group Animals randomized at 50-80 mm3 Comparisons across arms *p<0.05, ***p<0.001, ****p<0.0001 % TGI MC38 EMT6 4T1 Anti-PD-1 54 -8 6 CRB
Slide 69: Blockade of avb8 with anti-PD-1 Increased TIL Populations in EMT6 Tumors
Blockade of ⍺vβ8 in Combination with anti-PD-1 Increased TIL Populations in Immune Excluded EMT6 Tumors Source(s): Corbus data on file **** *** **** **** **** *** **** **** Ki67+CD4 T Cells Ki67+CD8 T Cells CD4 T Cells CD8 T Cells Tumor Size * *** * **** ** *** ** *** ** **** * **** * Treatment Days
Slide 70: CRB-601 Reshapes The Landscape Of Effector T and NK Cells in MC38 Tumors
CRB-601 Reshapes The Landscape Of Effector T and NK Cells in MC38 Tumors Source(s): Corbus data on file
Slide 71: Applying a Proprietary Algorithm To Define The Clinical Focus for CRB-601
Applying a Proprietary Algorithm To Define The Clinical Focus for CRB-601 A multi-parametric, immune-focused algorithm has refined indications for CRB-601 The combination of immune features and gene expression profiles have identified 9 indications for clinical priority High Low Quartiles Source(s):
Slide 72: Patient Selection Strategies Will Enhance the Probability of Success
Patient Selection Strategies Will Enhance the Probability of Success Source(s): Corbus proprietary analysis: Log2 fold change of Nectin-4 expression as a ratio to normal tissue Controls Ovarian Melanoma Breast Colon Prioritization of indications with differential gene expression vs. normal tissues w
Slide 73: Expected Milestones
Expected Milestones IND cleared January 2024 First patient dosed Summer 2024 Dose escalation and confirmation 2nd Half of 2024
Corbus Pharmaceuticals Holdings — Investor Presentation (June 2024) on 6ix